Travere Therapeutics Q3 2024 GAAP EPS $(0.70), Inline, Sales $62.90M Beat $59.70M Estimate
TRAVERE THERAPEUTICS INC -0.48% Post
TRAVERE THERAPEUTICS INC TVTX | 18.47 18.47 | -0.48% 0.00% Post |
Travere Therapeutics (NASDAQ:
TVTX) reported quarterly losses of $(0.70) per share which met the analyst consensus estimate. The company reported quarterly sales of $62.90 million which beat the analyst consensus estimate of $59.70 million by 5.35 percent. This is a 69.56 percent increase over sales of $37.09 million the same period last year.